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Forty years of repeated screening: the significance of carcinoma in situ
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Summary Two cohorts of women born in 1914-18 and 1929-33 who participated in a cervical screening
programme have been followed for over 40 years. Age-specific incidence rates of squamous carcinoma of the
cervix by rank of smear and length of interval between smears are reported. The younger cohort, who had
undergone more frequent screening, had lower rates of invasive disease. From these incidence rates, estimates
of false-negative rates and regression rates for carcinoma in situ have been made. The false-negative rate was
estimated to be about 15%. Regression seemed more frequent in younger than in older women. For the
younger cohort it was estimated to be 72% and in the older 47%. A comparison of the rates of in situ
carcinoma with those of invasive disease suggests that the screening of the younger cohort reduced the rate of
invasive disease to at least one-half or one-third of what it would have been if screening had commenced later.
Rates of disease appear less dependent on age than previously thought and are consistent with causation by an
infective agent.
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A cervical cytology screening programme was established in
British Columbia in 1949. In the early 1970s, when
approximately 85% of women aged 20 years and over in the
province were enrolled in the programme (Boyes et al., 1981),
an investigation into the true incidence and prevalence of
cancer of the cervix was carried out in two cohorts of women
(Boyes et al., 1982). Cohort I consisted of women born in the
years 1914-18 and cohort II were those born in the years
1929-33. The two cohorts differed in age by 15 years and were
chosen in order that the rates of various stages of the disease
could be investigated over a wide age range.
This study, which involves an updating of the earlier one,
reports age-specific incidence rates for carcinoma in situ or
invasive cancer in the two cohorts over a period of more than
40 years, 1949-92. The age range covered is from 16 to 78
years. During the last few decades many reports have
documented a decrease in invasive disease in the western
world. It is not clear what proportion of this decrease is
owing to the earlier detection and treatment of dysplasia and
carcinoma in situ. Soon most women in North America and
western europe will have regular cervical smears from their
early adult life, it is so important to assess the effect of such
screening on future incidence rates of invasive disease.
Subjects and methods
The two original cohorts comprised women who, before
1970, had had at least one smear, had undergone at least one
gynaecological surgical procedure generating a pathology
report, or had died of cervical cancer. In total, 119 153
women were included: 52 452 of whom were in cohort I and
66 701 in cohort II. In its cytology laboratory the British
Columbia Cancer Agency maintains records of all cytology
smears and gynaecological histology records for all women
screened or treated in the province. In the early 1970s the
handwritten records for the two cohorts were taken from the
cytology laboratory, edited and recorded on magnetic tape.
Each smear or pathology report formed one record on the
tape and each record contained identifying information about
the women concerned. The identifying information consisted
of the following: last name, first eight characters of first
name, middle initial, birth month, birth year, first four
characters of husband's first name. The smear report
information that was recorded was the class of the smear
(I-V) as read by the technician and the unique identifying
number for that smear. For those women who later
developed an abnormality, a reviewed class of the smear
was also given. It was used as the basis of the analyses in the
former paper but in this paper only the class as initially read
by the technician has been used. The pathology report
contained the type of tumour cells (squamous, adeno or
mixed), the stage of the disease and the treatment.
Before the updating of the cohort data was attempted it
was realised that, for many of the women, no post-1969
records would exist, since, before or soon after 1970, some of
the women would have died from causes other than cervical
cancer, some would have had a hysterectomy and some
would have left the province. During the 1970s some culling
of the files in the cytology laboratory took place. The files of
women who had had nothing but negative smears, no
histology and had not had a smear taken in the previous 7
years, or were known to be dead, were deleted. Interpolating
from the data on annual terminations of surveillance, it
would appear that the files of approximately 10% of the
women were removed.
Before proceeding with the update an attempt was made
to estimate from the smear and pathology records of the
original cohorts that were on magnetic tape the number of
women who had a very low probability of being linked. They
fell into two groups. The first group were women without
histology records and only a single smear which was taken
before 1967. The authors considered that women below age
55 with a gap without a smear in the years 1967-70 (when
many families returned to the eastern provinces) and with
only a single smear preceding, was a strong indication of a
transient resident. The second group were those who, before
1970, had had a hysterectomy for reasons other than cervical
cancer or its precursive abnormalities, or who had died of
cervical cancer. In cohort I, 12 923 women fell into these two
groups, and in cohort II 14 537. These women, however,
were included in all matching attempts since it was easier to
leave their records in the files and because there was a slight
probability that a linkage might be made.
Two methods of matching were used. One was to search
the files at the cytology laboratory for each unique smear
number included in the original cohort study. A successful
match on these numbers enabled us to identify the woman in
the cytology files and, from this, update our records. The
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second method was a probabilistic linkage based on the
woman's name and other identifying information. This
helped in the updating of two groups of women, those
whose earlier records had been culled from cytology files in
the 1970s but who had generated later records in the file, and
those whose records were mistakenly in two or more separate
files at the cytology laboratory. The first group of women
might have moved out of the province for a few years or
moved to a remote area of the province without easy access
to a physician. The second group were women who, because
of some error (perhaps misspelling of a name, for example,
Margaret McKenzie or Marg Mackenzie, or perhaps a
change of family physician), had had their records put into
two or more files.
The result of these two matching processes was that the
files of 28 769 women in cohort I and 42 468 women in
cohort II were linked. Using as a base the number of women
in the original cohorts thought to be linkable, the linkage
rates were 73% in cohort I and 81% in cohort II.
Undoubtedly because of our conservative linkage policy,
some women in the cohort whom we did not manage to link
continued to have smears after 1969. For example, in the case
of common surnames, if anything other than a minor
disagreement was present on any of the identifiers then
linkage was not performed. Therefore, the women who were
linked tended to be those who stayed with the same physician
(a physician identifier was attached to the smear submission
form but not recorded in the cohort data) or those who were
consistent in the reporting of their ages and names.
Results
The women in the younger cohort had an average of 9.78
smears with a mean interval of 20.87 months between the
smears, whereas the women in the older cohort averaged only
8.02 smears with a mean interval of 22.59 months.
Before the following analyses were carried out, smear
records that appeared to have been taken for diagnostic
purposes not screening purposes, were eliminated. Any
cluster of two or more smears in which consecutive smears
were less than 6 months apart was amalgamated into a single
smear, which was then assigned the highest class observed in
the cluster and the date of the first smear in the cluster.
The rates of disease that are presented pertain to
squamous cell or mixed cell carcinoma of the cervix. Table
la and b sets out the incidence rates (R) of carcinoma in situ
or invasive cancer by the number of previous smears the
women have had and by the screening interval immediately
preceding the smear. Only women who entered the
programme with a class I smear are included in this table.
Women ceased contributing to the table when they had a
hysterectomy, when they developed dysplasia or worse, or
when they had had their last smear.
The rank of a smear is one plus the number of previous
smears that the woman has had. The numerator (n) of the
rates is a count of the cases for the specified rank and
interval. The denominators are the sums of the person-years
for all smear intervals of a given rank. For example, if a 45-
year-old woman entered with a normal smear, had a second
smear which was normal 12 months later, and had an
abnormal smear 36 months after that, followed by a cone
biopsy showing carcinoma in situ, her contribution to the
numerator would be as a count of 1 in the interval category
for 36-47 months and smear rank 3 in the 45-49 year age
group. Her contribution to the denominator would consist of
two components. The first would be an addition of 12
months in the interval category for 12-23 months and smear
rank 2 in the 45-49 year age group. The second would be an
addition of 18 months (half of 36 months) in the interval
category for 36-47 months and for smear rank 3 in the age
group 45-49. This assumes that the conversion to the
abnormal state took place halfway between the time of the
abnormal smear and the previous normal smear. If the
example had been a woman with x normal smears and no
cytological or histological abnormalities she would make
x-1 separate contributions of person-years to the denomi-
nators of the appropriate cells, but nothing to any
numerator. For presentation purposes, the age groups have
been amalgamated in this table.
Table Ila and b is the same as Table Ia and b except that
the denominators of the rates are the number of smear
intervals of the specified length and smear rank, not the
number of person -years at risk. In the case of the
hypothetical 45-year-old woman her denominator contribu-
tions would be two counts of 1 in the 45 -49 age grouping,
the first to the 12 -23 month interval and smear rank of 2,
and the second to the 36-47 month interval and smear rank
of 3. As for Table Ia and b, the age groups have been
amalgamated.
In both tables, and in both cohorts, the risk of carcinoma
in situ or invasive cancer decreases with the rank of the
smear. A similar decrease in invasive cancer with the rank of
the smear has been documented elsewhere by Clarke and
Table I Cohort frequencies and incidence rates (per 1000 women-years) for carcinoma in situ or invasive cancer
Interval between smears (months)
Smear 0-11 12-23 24-35 36-47 48-59 60-119 120+ All
rank n R n R n R n R n R n R n R n R
(a) Cohort I
2 20 5.8 30 1.7 15 0.9 12 0.8 12 1.1 22 0.7 15 0.5 126 1.0
3 6 1.5 15 0.8 11 0.8 5 0.5 5 0.7 5 0.3 5 0.3 52 0.6
4 11 2.7 9 0.5 1 0.1 6 0.9 2 0.5 7 0.6 2 0.2 38 0.6
5 7 1.8 13 0.8 2 0.2 3 0.6 0 0.0 3 0.4 2 0.3 30 0.6
6 5 1.4 14 1.0 5 0.7 3 0.7 0 0.0 5 0.7 0 0.0 32 0.7
7 3 0.9 3 0.2 2 0.3 0 0.0 0 0.0 1 0.2 0 0.0 9 0.2
8 + 21 1.0 29 0.3 14 0.4 5 0.3 2 0.1 2 0.1 2 0.2 75 0.3
All 73 1.6 113 0.6 50 0.5 34 0.5 21 0.5 45 0.4 26 0.3 362 0.6
(b) Cohort II
2 32 5.6 59 2.4 51 2.3 32 1.8 17 1.2 54 1.5 16 0.5 261 1.7
3 23 3.6 46 1.7 37 2.0 15 1.2 10 1.2 15 0.8 5 0.3 151 1.4
4 25 3.9 40 1.5 15 1.0 6 0.7 4 0.6 4 0.3 2 0.2 96 1.1
5 16 2.6 20 0.8 13 1.0 5 0.7 4 0.8 3 0.3 0 0.0 61 0.8
6 8 1.3 29 1.3 8 0.7 5 0.8 0 0.0 1 0.1 0 0.0 51 0.8
7 8 1.5 18 0.8 4 0.4 7 1.2 0 0.0 1 0.1 0 0.0 38 0.6
8 + 38 1.0 91 0.5 30 0.4 19 0.5 8 0.3 7 0.2 0 0.0 193 0.5
All 150 1.9 303 1.0 158 1.0 89 0.9 43 0.7 85 0.6 23 0.3 851 0.9
n, number ofcases; R, rates per 1000 women -years.The significance of carcinoma in situ
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Anderson (1979), La Vecchia et al. (1984); MacGregor et al.
(1985) and others. With regard to the age-specific rates (not
shown here), when the cohort I women reached the age of
55 and cohort II the age of 40, the decrease became less
marked.
In Table Ia and b the rate of disease decreases across the
smear intervals with the highest rate being that for smears
taken less than 1 year apart. Conversely in Table Ila and b,
starting with the 12-23 month interval, the rates increase
across the intervals.
Table III relates the period of surveillance to the average
age of the cohort members and Figures 1 and 2 show the age-
specific incidence rates for carcinoma in situ or invasive
cancer per 1000 women. The rate for in situ carcinoma is
standardised for smear rank and interval. The circled points
are rates based on three or less cases. The peak in the cohort
II in situ curve, when the women were aged 30-34, is
probably caused by the introduction of oral contraceptives in
1962 because the increased incidence is largely among women
who had not had a smear for at least 2 years. Medical
practice was such that a smear was usually taken before a
prescription for a year's supply of oral contraceptives was
provided. The peak at age 40-44 may also be an artifact as it
coincides with the establishment of a culposcopy service in
the province. Figures 3 and 4 show the incidence of
carcinoma in situ and clinically invasive disease by calendar
year. The rates of carcinoma in situ are based on the number
of smears and they are not standardised since the screening
pattern differed little between the cohorts in any calendar
year. Standardisation did not have a major effect on the
comparison of the two curves except to reduce the magnitude
of the difference between them for the rates for the first 5
years of the programme.
Table IV displays age-specific disease rates based on
person-years for the overlapping ages of the two cohorts
along with the ratios of the rate in cohort II as compared
with the rate in cohort I. The rates for carcinoma in situ
have been standardised for rank and interval but those for
the clinical disease have not since, its incidence should be
largely independent of screening frequency. The purpose of
this table is to attempt to assess the reduction of clinical
disease in cohort II provided by the early screening and
treatment of carcinoma in situ. The ratios for carcinoma in
situ or invasive cancer clearly diminish with age. For clinical
disease the ratios do not show any clear pattern, the average
rate being 0.368, but they are generally substantially lower
than those for carcinoma in situ or invasive cancer.
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Figure 1 Standardised age-specific incidence of carcinoma in situ
or invasive cancer per 1000 woman-smears. Circled points are
based on three or fewer cases. -U-, cohort I; -C-, cohort II.
Table III Mean ages of cohorts during period of surveillance
Mean ages of cohort I Mean ages ofcohort II
Years (years) (years)
1951 -55 35-39 20-24
1956-60 40-44 25-29
1961-65 45-49 30-34
1966-70 50-54 35-39
1971-75 55-59 40-44
1976-80 60-64 45-49
1981 -85 65-69 50-54
1986-90 70-74 55-59
1991-95 75-79 60-64
Table II Cohort frequencies and incidence rates (per 1000 women-smears) for carcinoma in situ or invasive cancer
Interval between smears (months)
Smear 0-11 12-23 24-35 36-47 48-59 60-119 120+ All
rank n R n R n R n R n R n R n R n R
20
6
11
7
5
3
21
4.0
1.1
1.9
1.3
1.0
0.6
0.7
30
15
9
13
14
3
29
2.4
1.1
0.7
1.1
1.3
0.3
0.4
73 1.2 113 0.8
32
23
25
16
8
8
38
3.9
2.6
2.8
1.9
1.0
1.1
0.7
59
46
40
20
29
18
91
3.3
2.4
2.1
1.1
1.7
1.1
0.7
15
11
1
2
5
2
14
2.1
2.0
0.2
0.6
1.7
0.8
0.9
12
5
6
3
3
0
5
50 1.2 34
51
37
15
13
8
4
30
5.5
4.7
2.3
2.3
1.7
0.9
1.0
32
15
6
S
5
7
19
2.8
1.8
3.2
2.0
2.4
0.0
0.8
12
5
2
0
0
0
2
4.7
3.3
2.0
0.0
0.0
0.0
0.7
22
5
7
3
5
2
4.4
2.1
4.0
2.4
4.5
1.1
0.4
15
5
2
2
0
0
2
7.8
5.2
3.2
4.9
0.0
0.0
2.3
126
52
38
30
32
9
75
3.3
1.6
1.3
1.2
1.4
0.5
0.6
1.8 21 2.1 45 2.6 26 4.9 362 1.2
6.1
4.1
2.2
2.3
2.6
3.9
1.7
17
10
4
4
0
0
8
5.2
5.1
2.8
3.4
0.0
0.0
1.5
54
15
4
3
1
7
9.9
5.6
1.9
1.7
0.7
0.7
1.1
16
S
2
0
0
0
0
8.1
5.2
2.9
0
0
0
0
261
151
96
61
51
38
193
5.1
3.3
2.3
1.6
1.4
1.2
0.8
All 150 1.4 303 1.3 158 2.3 89 3.1 43 2.9 85 4.0 23 4.0 851 1.7
n, number of cases; R, rate per 1000 women.
(a) Cohort I
2
3
4
5
6
7
8+
All
(b) Cohort II
2
3
4
5
6
7
8+Discussion
In Tables Ia and b and Ila and b the decrease in incidence
with increasing smear rank is probably the result of three
factors. The first and most obvious one is that at least for
cohort II, the disease rates decrease with age and that age
and rank are inevitably correlated. Consequently, even
within a given age group, there will be some residual effect
of the decrease with age. The other factor is that of
selection. Fidler et al. (1968) showed that women who are at
a low risk of disease tend to be conscientious about having
regular smears. This is supported by examining the risk
associated with smear rank before and after 1970
(partitioned data not presented). Before 1970, when new
women were continuously entering the cohorts, there is a
marked association between smear rank and risk of disease;
after 1970, when no new women were entering, this
association is much less evident. Artifactual selection, in
that women who developed an abnormality were no longer
considered to be at risk, was also operating.
The increased risk across Table IIa and b is undoubtedly
due to the longer intervals between smears providing women
with a greater opportunity for developing the disease. The
fact that the incidence rates are not lowest in the shortest
interval, 0-11 months, suggests that the smear immediately
preceding the one in the 0-11 month interval may have been
a false negative. Fitting a regression line to the rates for the
six intervals longer than 11 months and extrapolating it to
the 0-11 month interval will give an 'expected' value for the
incidence rate for that interval. The difference between the
expected incidence rate and the observed rate should be the
rate of disease which can be attributed to false negatives. To
obtain the most accurate estimate it was necessary to use only
the data pertaining to smears of rank 2 since those smears
were the only ones where there was 100% certainty that the
previous smear was a class 1. Another complication was that
the incidence rates in the longer intervals could have been
reduced by regression and, as a consequence, the slopes of
the fitted lines would have been diminished. Using tables
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Figure 2 Incidence rate of clinical invasive cancer per 1000
woman-years. Circled points are based on three or fewer cases. -
*-, cohort I; -O-, cohort II.
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similar to TableII (a and b) but which contained only cases
of carcinoma in situ, fitted lines were calculated using 3,4,5
and 6 points for each cohort. False negative rates were then
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Figure 3 Incidence of carcinoma in situ or invasive cancer per
1000 woman-smears by 5 year periods. Circled points are based
on three or fewer cases. -U-, cohort I; -O-, cohort II.
0.30
0.25
0.20
4)
a)
c 0.15
')
._5
V
0.10
0.05
ii; 0D 0
S CD Ct CD f.
a) CY) a) a) e
Years
00
00 00
Figure 4 Incidence of clinical invasive carcinoma per 1000
woman-years by 5 year periods. Circled points are based on
three or fewer cases. ---, cohort I; -E-, cohort II.The significance of carcinoma in situ
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Table IV Ratios of incidence rates (per 1000 women-years) for
overlapping age groups
Carcinoma in situ or invasive Clinically
cancer invasive
Age Standardised incidence rate Incidence rate
years Cohort I Cohort II Ratio Cohort I Cohort II Ratio
35 -39 0.186a 0.899 4.83a 0.239a 0.053 0.22a
40-44 0.435 0.982 2.26 0.138 0.053 0.38
45-49 0.466 0.604 1.30 0.110 0.053 0.48
50-54 0.530 0.362 0.68 0.141 0.035 0.25
55 -59 0.585 0.231 0.39 0.097 0.030a 0.31a
60-64 0.779 0.069a 0.09a 0.145 0.OOOa 0.O0a
aRate or ratio based on three or less cases in a cohort.
calculated from the line which produced the best fit. For
cohortI, the fit was best when all six intervals were used,
producing an estimate of 14%. The estimated false negative
rate for cohortII, 18%, was obtained by fitting only the first
three intervals, 12-23, 24-35, and 36-47 months. It is not
surprising that the fit was best with just three points since
cohort II seemed to have a very high rate of regression in the
early years of the programme when most of the women were
having their second smear. From these calculations it would
appear that approximately 1 in 6 or 7 cases of in situ were
missed because of false negative smears. These mistakes could
have been the result of either laboratory error or failure of
the physician to obtain an adequate smear. Using tables
similar to TableII (a and b) but which contained only cases
of invasive cancer, the false negative rates were estimated to
be 36% for cohortI and 27% for cohortII. These last two
estimates were obtained by fitting the rates for all six
intervals. The decrease in the sensitivity of the smear test
with disease progression points to the confounding of risks
inherent in increasing the interval between screens.
Tables Ia and b and Ila and b show opposite trends in risk
across the smear intervals. The decreasing incidence across
the screening intervals in Table Ia and b is probably a
reflection of regression. In the shorter screening intervals, the
rate of detection of transient lesions should be higher because
there are more screenings per person-year and, hence, more
opportunity to detect an abnormal state. Ignoring the rate in
the 0-11 month interval on the grounds that it may be
contaminated by previous false negatives, and testing the
decrease across the remaining intervals, shows a significant
(P=0.003, P =0.007) linear association in both cohorts
between the rate of carcinoma in situ or invasive cancer
and the length of the screening interval. Applying the same
analyses to the incidence of clinical cancer demonstrates that
there is no significant decrease in the rates across the
screening intervals (P=0.781, P=0.599), reflecting the fact
that invasive cancer does not regress.
A crude estimate of the proportion of carcinoma in situ
that does not regress can be obtained by dividing the overall
incidence rate (person-years) for the longest interval
(120+months) by the overall incidence rate for the shortest
interval (0-11 months). As we have just demonstrated,
however, the magnitude of the latter rate is inflated by false
negatives from the previous smear and, therefore, it is
probably wiser to use the rate for the second shortest
interval and assume that the resulting ratio may be an
overestimate. The complement of this proportion may then
be an underestimate of the proportion of carcinoma in situ
that does regress. For cohort I this estimate is 1-(0.33/
0.62)=0.47, and for cohort II it is 1-(0.27/0.96)= 0.72.
These figures are higher than those derived by different
methods in the original paper by Boyes et al. (1982), but that
is to be expected as a longer time span is covered. The figures
are lower than those derived from Swedish data (88%) by
Gustafsson and Adami (1989) whose data covered approxi-
mately the same age range and time span. In cohort II the
regression is greater for women aged under 40 than for
women aged 40 and over but, in cohort I, the data are
insufficient for women aged under 40 to be able to assess if
the same holds true. For the overlapping ages of the two
cohorts, 40-65, the rate was 54.4% for cohort I and 65.4%
for cohort II. From these results it is not possible to conclude
if the difference in estimated regression rates is caused by
intrinsic cohort disparities or differences in the average age at
which screening took place.
Figures 1 and 2 show that, while the incidence of
carcinoma in situ may be higher in cohort II than in cohort
I, the incidence of clinical disease is lower. The crucial
question is whether the lower rate in cohort II is the result of
lifestyle differences, whether it is the accrued benefit of early
detection and treatment of dysplasia and carcinoma in situ,
or whether it is a mixture of both. Beral (1974) reported
higher rates of invasive disease in England and Wales in
women born in the years 1914- 18 than in women born in the
years 1929-33. On average the ratio of the rates was
approximately 0.75. The rates were based on the years before
1972 when little screening was being carried out in England
and Wales. Gustafsson and Adami (1989) also reported
higher rates for the 1914-18 cohort than for the 1929-33
cohort in Sweden. The ratio of the rates of their cohorts was
approximately 0.50. These rates were based on cases
occurring before 1982 when a fairly extensive screening
programme had been operating for almost 20 years.
However, the frequency of screening was lower than for the
British Columbia cohorts.
Figure 3 shows the rates of carcinoma in situ or invasive
cancer in the two cohorts by quinquennial periods. The
shapes of the two curves are similar except that in the earlier
periods the rates for cohort II are considerably higher than
those for cohort I. Some of this gap between the two curves
is undoubtedly the result of a higher regression rate in the
younger women, but higher regression cannot be the total
explanation since Figure 1 shows that the age-specific rates
are also higher in cohort II up until the women are nearly 50
years old. Together Figures 3 and 4 suggest that the incidence
of the disease may not be nearly so age dependent as
previously thought. The incidence rates displayed in Figure 3
are consistent with the cohorts having been exposed to some
causative agent in the late 1940s or early 1950s. Beral (1974)
related annual cervical cancer cohort mortality to the annual
incidence ofgonorrhoea in Scotland and England and Wales,
which was used as a measure of the incidence of sexually
transmitted infections. The shapes of the cervical cancer and
the gonorrhoea curves were similar.
Although the carcinoma in situ rates for cohort II exceed
those for cohort I up until the younger women reach 50, the
reverse is generally true for invasive disease (Figures 2 and 4).
The ratios of the incidence ofclinically invasive disease in the
two cohorts as shown in Table IV suggest that the early,
regular screening of cohort II reduced the incidence of
clinical disease to at least one-half or one-third of what it
would have been had screening commenced when the women
reached age 35.
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